表紙
市場調查報告書

茲卡病毒感染疾病:開發中產品分析

Zika Virus Infections - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410983
出版日期 內容資訊 英文 244 Pages
訂單完成後即時交付
價格
Back to Top
茲卡病毒感染疾病:開發中產品分析 Zika Virus Infections - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 244 Pages
簡介

茲卡病毒感染主要是由白線斑蚊傳播的病毒引起。茲卡病毒屬於黃病毒科的一員。症狀包括發熱,皮疹,結膜炎,肌肉和關節疼痛,不適和頭痛。風險因素包括在熱帶和亞熱帶地區逗留。茲卡病毒可以透過性交傳染。治療的目的是用點滴和藥物緩解症狀(關節疼痛和發燒)。

本報告提供茲卡病毒感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

茲卡病毒感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

開發治療藥的企業

  • Bharat Biotech International Ltd
  • Biken Inc
  • BioCryst Pharmaceuticals Inc
  • Biotron Ltd
  • CaroGen Corp
  • Codagenix Inc
  • Ennaid Therapeutics LLC
  • Etubics Corp
  • GeneOne Life Science, Inc.
  • GeoVax Labs Inc
  • Hawaii Biotech Inc
  • Hemispherx Biopharma Inc
  • HSRx Group
  • Humabs BioMed SA
  • Immunovaccine Inc
  • Kineta Inc
  • Mymetics Corp
  • NewLink Genetics Corp
  • Novavax Inc
  • OXIS International Inc
  • PaxVax Inc
  • Pharos Biologicals LLC
  • Plex Pharmaceuticals Inc
  • Prokarium Ltd
  • Protein Sciences Corp
  • Regeneron Pharmaceuticals Inc
  • Replikins Ltd
  • Sanofi Pasteur SA
  • Sirnaomics Inc
  • Spotlight Innovation Inc
  • Starpharma Holdings Ltd
  • 武田藥品工業
  • Tamir Biotechnology Inc
  • TGV-Laboratories
  • Themis Bioscience GmbH
  • Valneva SE
  • Vaxart Inc
  • VaxInnate Corp
  • VBI Vaccines Inc
  • Visterra Inc
  • VLP Therapeutics LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11674IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H2 2019, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 15, 40, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 11 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Zika Virus Infections - Overview
    • Zika Virus Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Zika Virus Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Zika Virus Infections - Companies Involved in Therapeutics Development
    • Activirosomes Ltd
    • Acuitas Therapeutics Inc
    • AIM ImmunoTech Inc
    • Aravive Inc
    • Bharat Biotech Ltd
    • Biken Co Ltd
    • BioCryst Pharmaceuticals Inc
    • BioNet- Asia Co Ltd
    • Biotron Ltd
    • BravoVax Co Ltd
    • CanSino Biologics Inc
    • Chugai Pharmaceutical Co Ltd
    • Cidara Therapeutics Inc
    • Ciloa
    • Clayton Biotechnologies Inc
    • Cocrystal Pharma Inc
    • Codagenix Inc
    • Emergent BioSolutions Inc
    • Emergex Vaccines Ltd
    • Ennaid Therapeutics LLC
    • Enyo Pharma SA
    • Etubics Corp
    • Excivion Ltd
    • Future Medicine Co Ltd
    • GeneOne Life Science Inc
    • GeoVax Labs Inc
    • Greffex Inc
    • GT Biopharma Inc
    • Hawaii Biotech Inc
    • Heat Biologics Inc
    • HSRx Group
    • Humabs BioMed SA
    • IDBiologics Inc
    • Immunomodulation Inc
    • Imutex Ltd
    • IMV Inc
    • Inmunova SA
    • Inovio Pharmaceuticals Inc
    • Johnson & Johnson
    • KM Biologics Co Ltd
    • Macrophage Therapeutics Inc
    • Medigen Inc
    • Microbiotix Inc
    • Moderna Therapeutics Inc
    • Mymetics Corp
    • NanoViricides Inc
    • Novalex Therapeutics Inc
    • Palisades Therapeutics
    • Pharos Biologicals LLC
    • Phoenix Biotechnology Inc
    • Plex Pharmaceuticals Inc
    • Precision Virologics Inc
    • Prokarium Ltd
    • ProtInhi BV
    • Quratis Inc
    • Replikins Ltd
    • Riboscience LLC
    • Sanofi
    • Sementis Ltd
    • Spotlight Innovation Inc
    • Stabilitech Biopharma Ltd
    • Starpharma Holdings Ltd
    • Takeda Pharmaceutical Co Ltd
    • TechnoVax Inc
    • Themis Bioscience GmbH
    • Theravectys SA
    • Tiba Biotech LLC
    • Tychan Pte Ltd
    • Valneva SE
    • VBI Vaccines Inc
    • VenatoRx Pharmaceuticals Inc
    • Virocovax
    • Xenothera SAS
  • Zika Virus Infections - Drug Profiles
  • Zika Virus Infections - Dormant Projects
  • Zika Virus Infections - Discontinued Products
  • Zika Virus Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Zika Virus Infections, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Zika Virus Infections - Pipeline by Activirosomes Ltd, H2 2019
  • Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H2 2019
  • Zika Virus Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
  • Zika Virus Infections - Pipeline by Aravive Inc, H2 2019
  • Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H2 2019
  • Zika Virus Infections - Pipeline by Biken Co Ltd, H2 2019
  • Zika Virus Infections - Dormant Projects, H2 2019
  • Zika Virus Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Zika Virus Infections - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Zika Virus Infections, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top